Trial Profile
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Dec 2023
Price :
$35
*
At a glance
- Drugs Belumosudil (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms ROCKstar; The ROCKstar Study
- Sponsors Kadmon Holdings; Sanofi
- 15 Dec 2023 Status changed from active, no longer recruiting to discontinued, owing to difficulty in recruiting adolescent participants. This decision was made without any safety concerns.
- 23 Nov 2023 Planned End Date changed from 1 Jan 2026 to 8 Dec 2023.
- 23 Nov 2023 Planned primary completion date changed from 1 Jan 2026 to 8 Dec 2023.